Cargando…
Associations Between High Plasma Methylxanthine Levels, Sleep Disorders and Polygenic Risk Scores of Caffeine Consumption or Sleep Duration in a Swiss Psychiatric Cohort
Objective: We first sought to examine the relationship between plasma levels of methylxanthines (caffeine and its metabolites) and sleep disorders, and secondarily between polygenic risk scores (PRS) of caffeine consumption or sleep duration with methylxanthine plasma levels and/or sleep disorders i...
Autores principales: | Laaboub, Nermine, Gholam, Mehdi, Sibailly, Guibet, Sjaarda, Jennifer, Delacrétaz, Aurélie, Dubath, Céline, Grosu, Claire, Piras, Marianna, Ansermot, Nicolas, Crettol, Severine, Vandenberghe, Frederik, Grandjean, Carole, Gamma, Franziska, Bochud, Murielle, von Gunten, Armin, Plessen, Kerstin Jessica, Conus, Philippe, Eap, Chin B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8721597/ https://www.ncbi.nlm.nih.gov/pubmed/34987426 http://dx.doi.org/10.3389/fpsyt.2021.756403 |
Ejemplares similares
-
Insomnia disorders are associated with increased cardiometabolic disturbances and death risks from cardiovascular diseases in psychiatric patients treated with weight-gain-inducing psychotropic drugs: results from a Swiss cohort
por: Laaboub, Nermine, et al.
Publicado: (2022) -
Publisher Correction: Insomnia disorders are associated with increased cardiometabolic disturbances and death risks from cardiovascular diseases in psychiatric patients treated with weight-gain-inducing psychotropic drugs: results from a Swiss cohort
por: Laaboub, Nermine, et al.
Publicado: (2022) -
Identification of four novel loci associated with psychotropic drug-induced weight gain in a Swiss psychiatric longitudinal study: A GWAS analysis
por: Sjaarda, Jennifer, et al.
Publicado: (2023) -
Association Between Plasma Caffeine and Other Methylxanthines and Metabolic Parameters in a Psychiatric Population Treated With Psychotropic Drugs Inducing Metabolic Disturbances
por: Delacrétaz, Aurélie, et al.
Publicado: (2018) -
Olanzapine‐associated dose‐dependent alterations for weight and metabolic parameters in a prospective cohort
por: Schoretsanitis, Georgios, et al.
Publicado: (2022)